Clinical Edge Journal Scan

Prostate cancer: Patient-reported outcomes support hypofractionated radiotherapy


 

Key clinical point: Patient-reported outcomes were similar with hypofractionated vs. conventional radiotherapy at 5 years in patients with prostate cancer.

Major finding: There were no differences in the Expanded Prostate Cancer Index Composite or University of California Los Angeles Prostate Cancer Index in the overall bowel, urinary, and sexual symptoms between the 3 groups at 5 years.

Study details: Quality of life substudy of phase 3 randomized CHHiP trial of 2,100 patients with intermediate-risk prostate cancer who received conventional (74 Gy in 37 fractions over 7.4 weeks) or hypofractionated (60 Gy in 20 fractions over 4 weeks or 57 Gy in 19 fractions over 3.8 weeks) radiotherapy.

Disclosures: This study was supported by Cancer Research UK, Institute for Health Research Cancer Research Network, and National Health Service.

Source: Staffurth JN et al. Eur Urol Oncol. 2021 Sep 3. doi: 10.1016/j.euo.2021.07.005 .

Recommended Reading

The Precision Oncology Program for Cancer of the Prostate (POPCaP) Network: A Veterans Affairs/Prostate Cancer Foundation Collaboration(FULL)
Federal Practitioner
Clinical Edge Journal Scan Commentary: Prostate Cancer August 2021
Federal Practitioner
Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm
Federal Practitioner
Health-Related Quality of Life and Toxicity After Definitive High-Dose-Rate Brachytherapy Among Veterans With Prostate Cancer
Federal Practitioner
Clinical Edge Journal Scan Commentary: Prostate Cancer September 2021
Federal Practitioner
Old saying about prostate cancer not true when it’s metastatic
Federal Practitioner
Diagnosis of Prostate Cancer and Prostate-specific Antigen Level on Initial Prostate Biopsy: Does Race Matter?
Federal Practitioner
Methods of Identifying Real World mCRPC Patients from the Veterans Health Administration System
Federal Practitioner
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-free DNA
Federal Practitioner
CRPC: Add-on apalutamide maintains quality of life
Federal Practitioner